[MO5] Mini-Oral Session 5　肝胆膵2（HCC・膵がん）
【E】

[MO5-2] Cabozantinib may enhance efficacy of anti-PD-1 therapy in hepatocellular carcinoma through suppression of MDSCs

^○Da-Liang Ou¹, Li Lin¹, Chia-Lang Hsu^1,2, Cheng-Zhe Jian¹, Bin-Shyun Lee¹, Ann-Lii Cheng^1,3,4, Chiun Hsu^1,3,4 (1.Graduate Institute of Oncology, College of Medicine, National Taiwan University, 2.Department of Medical Research, National Taiwan University Hospital, 3.National Taiwan University Cancer Center, 4.Department of Oncology, National Taiwan University Hospital)